$1,318.00
This Market Spotlight report covers the Waldenström Macroglobulinemia market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.
This Market Spotlight report covers the Waldenström Macroglobulinemia market, comprising key marketed and pipeline drugs, probability of success, clinical trials, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Chemotherapy
8 Targeted drugs
8 Biological therapy or immunotherapy
9 Plasmapheresis
9 Stem cell transplantation (SCT)
10 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Brukinsa for WM (December 16, 2019)
24 Mavorixafor for WM (July 17, 2019)
26 KEY UPCOMING EVENTS
27 PROBABILITY OF SUCCESS
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
32 Recent events
33 BIBLIOGRAPHY
33 Prescription information
34 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of WM, 2017–26
14 Figure 2: Incident cases of WM, by age, 2017
17 Figure 3: Overview of pipeline drugs for WM in the US
18 Figure 4: Pipeline drugs for WM, by company
18 Figure 5: Pipeline drugs for WM, by drug type
18 Figure 6: Pipeline drugs for WM, by classification
24 Figure 7: Brukinsa for WM (December 16, 2019): Phase III – ASPEN (vs. Ibrutinib)
26 Figure 8: Key upcoming events in WM
27 Figure 9: Probability of success in the WM pipeline
29 Figure 10: Clinical trials in WM
29 Figure 11: Top 10 drugs for clinical trials in WM
30 Figure 12: Top 10 companies for clinical trials in WM
30 Figure 13: Trial locations in WM
31 Figure 14: WM trials status
32 Figure 15: WM trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of WM, 2017–26
13 Table 2: Incident cases of WM, by gender, 2017
16 Table 3: Marketed drugs for WM
20 Table 4: Pipeline drugs for WM in the US
23 Table 5: Brukinsa for WM (December 16, 2019)
25 Table 6: Mavorixafor for WM (July 17, 2019)
28 Table 7: Historical global sales, by drug ($m), 2015–19
28 Table 8: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!